Researchers at the University of Munich in Germany have found that circulating tumour cells (CTC), cancer cells circulating in the blood, can be detected before and after chemotherapy treatment, and so can be helpful in identifying patients who are likely to have a recurrence of cancer after the procedure.
Addressing a press conference at the European Cancer Conference (ECCO 14) on Monday, Dr. Julia Juckstock said that the results could help improve the design of trials of chemotherapy in breast cancer, and reduce costs to health services.
Led by Dr. Brigitte Rack, the research team analysed the role of CTCs in blood at the first diagnosis of breast cancer and during adjuvant chemotherapy and endocrine treatment.
The researchers analysed blood samples from 1,767 node-positive and high-risk node-negative breast cancer patients before the start of their treatment, and compared the results to those obtained from 852 of the same patients after completion of chemotherapy.
We found that 10 percemt of patients whose blood was sampled before the start of treatment had more than one CTC, and 5 percent of these patients had more than two CTCs in approximately 20 ml of blood, Dr. Juckstock said.
The scientists found that among the 24 healthy individuals used as controls, none showed more than one CTC.
They said that among the 852 patients whose blood was analysed post-treatment, 11 percent were CTC positive before the start of treatment, while 7 percent had more than one CTC after completion of chemotherapy.